The MarketWatch News Department was not involved in the creation of this content.-- Commercial sponsorship integrates EvE Bio's growing field--defining "pharmome" map - 385,572 ri ...

The top-line data from the first cohort demonstrate a favorable safety profile, with no serious adverse events reported and the treatment generally well-tolerated across all participants. Additionally ...

COCP READ THE FULL COCP RESEARCH REPORT Business Update Phase 1b Challenge Study of CDI-922 to be Initiated in 1H26 Cocrystal Pharma, Inc. (NASDAQ:COCP) is developing CDI-988 as a prophylaxis and ...

Discover why Recursion Pharmaceuticals, Inc. stands out in AI drug discovery, but faces valuation risks. Click for my look at ...

Traditionally, developing a new drug can take over a decade, but AI technology is changing that timeline. Major pharmaceutical companies like Pfizer and AstraZeneca are leveraging AI to accelerate the ...

BOTHELL, Wash., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial results for the three and nine months ended September 30, 2025, ...

Pfizer is launching the first clinical trials for its PD-1xVEGF drug, while Akeso detailed the first overall survival win for ...

While AI has accelerated drug discovery, the same technology can address clinical trial bottlenecks that have persisted for ...

Q3 2025 Earnings Call November 13, 2025 9:00 AM ESTCompany ParticipantsPanna Sharma - President, CEO & DirectorDavid ...

Expects to Submit Conditional Marketing Approval Application in Europe for Iopofosine I 131 in Refractory (post-BTKi) Waldenstrom’s ...

Promising results from a pivotal Phase 3 clinical trial of an investigational heart-attack drug were announced this week, ...

With the rapid advancements in computer technology and bioinformatics, the prediction of protein-ligand binding sites has ...